Betadine bucal 100 mg/ml solucion bucal

Label: information for the user

Betadine oral 100 mg/ml oral solution

Povidone iodine

Read this label carefully before starting to use this medication, as it contains important information for you.

Follow exactly the medication administration instructions contained in this label or those indicated by your doctor, pharmacist, or nurse.

-Keep this label, as you may need to refer to it again.

-If you need advice or more information, consult your pharmacist.

-If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this label. See section 4.

-You should consult a doctor if your condition worsens or does not improve.

The povidone iodide, active ingredient of this medication, is an antiseptic (that destroys the germs that produce infections) that contains iodine.

Betadine is indicated as a buccal and pharyngeal antiseptic that is used for the symptomatic relief of mild oral infections such as mouth sores and small ulcers. Bad breath. Hoarseness and cough.

Do not use Betadine bucal

• If you are allergic to povidone iodine or any of the other components of this medication (listed in section 6).
• If you have hyperthyroidism or other acute thyroid diseases.
• - Before, during, and after administration of radioactive iodine
• - With products that contain mercury due to the formation of a substance that can damage the skin.
• In children under one year.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to use Betadine bucal.

Do not ingest. Avoid contact with eyes, ears. Consult your doctor if symptoms persist, worsen, or fever appears.

Patients with goiter, thyroid nodules, or other non-acute thyroid diseases have a risk of developing hyperthyroidism with the administration of high doses of iodine. In these patients, it should not be applied for prolonged periods of time and in extensive areas of skin unless strictly indicated. Even at the end of treatment, be aware of early symptoms of possible hyperthyroidism and, if necessary, control thyroid function.

Do not use before or after an iodine radioactive scan or treatment of thyroid cancer with radioactive iodine.

In oral use, be cautious to avoid aspiration of Betadine bucal in the respiratory tract as it may cause complications such as pneumonitis. It is essential in intubated patients.

Thyroid function tests should be performed in case of prolonged use.

Children

Newborns and young children have a higher risk of developing hypothyroidism. If used in children, it is essential to control thyroid function.

Do not use in children under 1 year.

Use of Betadine bucal with other medications

Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.

Do not use with mercury derivatives, with silver, with hydrogen peroxide, or with taurolidina (antiseptics).

It is essential to avoid continuous use in patients undergoing simultaneous therapy with lithium (used in psychiatry).

When used at the same time or after antiseptics with octenidine, dark discoloration of the affected areas may appear.

Interaction with diagnostic tests:The use of povidone iodine may lead to errors in tests with toluidine or guaiacol to determine hemoglobin or glucose in feces or urine. It may also interfere with thyroid tests and treatments with radioactive iodine. Inform your doctor when you need to undergo any type of diagnostic test.

Inform your doctor if:

• Symptoms do not improve or worsen
• You have received treatments with radioactive iodine in the last 4 weeks
• You have an allergy or dermatitis as redness, small blisters, itching, or rash that may appear immediately.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.

Use only if strictly indicated, and your use should be maintained at the absolute minimum. Avoid continuous use.

Your use may produce transient hypothyroidism in fetuses and newborns. It may be necessary to control thyroid function in children.

You should consult with your doctor about use in children between 1 and 2 years.

Driving and operating machinery

Betadine does not affect the ability to drive or operate machinery.

Follow exactly the medication administration instructions contained in this leaflet or those indicated by your doctor, pharmacist, or nurse. If in doubt, ask your doctor, pharmacist, or nurse.

Use as mouthwashes or oral rinses. After brushing your teeth, dilute one full cap of the product in half a glass of water. Repeat 2 or 3 times a day.

If you use more Betadine oral than you should

In case an excessive amount of the product is applied and skin irritation occurs, wash the affected area with plenty of water, discontinue treatment, and if irritation continues, consult a doctor.

Symptoms may include abdominal pain, anuria (suppression or decrease in urine), circulatory, respiratory, and metabolic problems. Excessive iodine may cause goiter, hypothyroidism, and hyperthyroidism.

In case of accidental ingestion, visit a medical center or call the Toxicological Information Service, phone: 91 562 04 20, indicating the product and the amount ingested.

If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.

Like all medications, this medication may produce adverse effects, although not all people will experience them.

In rare cases where irritation or an allergic reaction occurs, discontinue treatment and wash the affected area with water.

Rare adverse effects (may affect between 1 and 10 of every 10,000 people) are hypersensitivity and contact dermatitis that manifest with red skin, small blisters, and itching.

Very rarely (may affect fewer than 1 of every 10,000 people), severe allergic reactions (anaphylaxis), hyperthyroidism with tachycardia and agitation, and angioedema (allergic swelling) have been observed.

Other adverse effects of unknown frequency have been hypothyroidism, electrolyte imbalance, metabolic acidosis, pneumonitis (complications of aspiration – see section “Warnings and Precautions”), acute renal failure, abnormal blood osmolarity, dry skin, skin discoloration, and chemical burns on the skin.

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance for Human Use Medications: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.

Keep this medication out of the sight and reach of children.

No special storage conditions are required.

Do not use this medication after the expiration date that appears on the packaging after CAD or EXP. The expiration date is the last day of the month indicated.

Medications should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and unused medications. By doing so, you will help protect the environment..

Betadine Oral Composition

The active ingredient is povidone iodine. Each milliliter of solution contains 100 mg of povidone iodine.

The other components (excipients) are: glycerol (E 422), peppermint aroma, sodium saccharin, sodium hydroxide (E 524), and purified water.

Product appearance and packaging contents

Brown-colored solution.

Presented in high-density polyethylene bottles with a black cap and reducer containing 125 ml.

Marketing authorization holder andresponsible manufacturer

Marketing authorization holder

Cooper Consumer Health B.V.

Verrijn Stuartweg 60,

1112 AX Diemen,

Netherlands

Responsible manufacturer

MEDA Manufacturing, Bordeaux

Av. Pdt. J. F. Kennedy. BP 100

Merignac – Cedex

F-33700

France

For more information about this medication, please contact the local representative of the marketing authorization holder:

Vemedia Pharma Hispania, S.A.

C/ Aragón, 182, 5th floor

08011 - Barcelona

Spain

Last review date of this leaflet:August 2022

The detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) https://www.aemps.gob.es/